Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

GLMD Galmed Pharmaceuticals

Watchlist
0.615
-0.035-5.35%
Close 07/01 16:00 ET
0.61500.00%
Post Mkt Price 07/01 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
0.699
Open
0.643
Turnover
25.82K
Low
0.585
Pre Close
0.650
Volume
40.76K
Market Cap
15.43M
P/E(TTM)
Loss
52wk High
3.420
Shares
25.09M
P/E(Static)
Loss
52wk Low
0.417
Float Cap
12.17M
Bid/Ask %
-66.67%
Historical High
27.060
Shs Float
19.79M
Volume Ratio
0.24
Historical Low
0.417
Dividend TTM
--
Div Yield TTM
100
P/B
0.63
Dividend LFY
--
Div Yield LFY
16254.88%
Turnover Ratio
0.21%
Amplitude
17.52%
Avg Price
0.633
Lot Size
1
Float Cap
12.17M
Bid/Ask %
-66.67%
Historical High
27.060
Shs Float
19.79M
Volume Ratio
0.24
Historical Low
0.417
Dividend TTM
--
P/B
0.63
Dividend LFY
--
Turnover Ratio
0.21%
Amplitude
17.52%
Avg Price
0.633
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
CEO: Baharaff, Allen
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top